Biostatistics and Clinical Trial Interpretation: Key Concepts and Applications

Measures of Central Tendency and Dispersion

Mean, Median, and Mode

Measures of central tendency are used to describe the center of a dataset. The mean is the arithmetic average, the median is the middle value, and the mode is the most frequently occurring value.

• Mean: $\text{Mean} = \frac{\sum x_i}{n}$

• Median: The value separating the higher half from the lower half of a data sample.

• Mode: The value that appears most frequently in a dataset.

Example: For ages 20, 25, 30, 35, 40, the mean is 30, the median is 30, and there is no mode.

Standard Deviation

Standard deviation (SD) measures the spread of data points from the mean. A low SD indicates data points are close to the mean, while a high SD indicates greater dispersion.

• Formula: $\text{SD} = \sqrt{\frac{\sum (x_i - \bar{x})^2}{n-1}}$

Example: Dataset A: 20, 25, 30, 35, 40 (SD ≈ 7.91); Dataset B: 10, 20, 30, 40, 50 (SD ≈ 15.81).

Sample Statistics vs Population Parameters

Definitions and Applications

Sample statistics are calculated from a subset of the population and used to estimate population parameters, which describe the entire population.

• Sample Mean: Average age from a sample of 100 individuals.

• Population Mean: Average age of all individuals in a city.

Confidence Intervals and Statistical Significance

Confidence Interval of the Mean

A confidence interval (CI) provides a range within which the true population parameter is likely to lie, with a specified level of confidence (e.g., 95%).

• Formula: $\text{CI} = \bar{x} \pm z \frac{\sigma}{\sqrt{n}}$

Example: If the mean sleep time is 7 hours with a 95% CI of ±0.5 hours, the true mean is likely between 6.5 and 7.5 hours.

P-value and Statistical Significance

The p-value measures the strength of evidence against the null hypothesis. A result is statistically significant if the p-value is less than the chosen alpha level (commonly 0.05).

• Example: p-value of 0.01 indicates strong evidence against the null hypothesis.

Risk, Odds, and Ratios

Risk and Risk Ratio

Risk is the probability of an event occurring. The risk ratio (RR) compares the risk between two groups.

• Formula: $\text{RR} = \frac{\text{Risk in treatment group}}{\text{Risk in control group}}$

Example: If risk in smokers is 20% and in non-smokers is 10%, RR = 2.

Odds and Odds Ratio

Odds represent the likelihood of an event occurring versus not occurring. The odds ratio (OR) compares odds between two groups.

• Formula: $\text{OR} = \frac{\text{Odds in treatment group}}{\text{Odds in control group}}$

Diagnostic Test Evaluation

Sensitivity, Specificity, and Predictive Values

These metrics assess the performance of diagnostic tests:

• Sensitivity: Ability to correctly identify those with disease (true positive rate).

• Specificity: Ability to correctly identify those without disease (true negative rate).

• Positive Predictive Value (PPV): Probability that a positive test result indicates disease.

• Negative Predictive Value (NPV): Probability that a negative test result indicates absence of disease.

Hazard Ratio and Survival Analysis

Hazard Ratio (HR)

The hazard ratio compares the rate of occurrence of an event between two groups over time, often used in survival analysis.

• HR = 1: No difference between groups.

• HR < 1: Lower risk in treatment group.

• HR > 1: Higher risk in treatment group.

Biostatistics Assignment: Calculations and Interpretation

Vaccine Efficacy and Risk Reduction

Using the provided table, calculate:

Group	Influenza Yes	Influenza No	Total
Vaccine Yes	20 (8.3%)	220 (91.7%)	240
Placebo No	80 (36.4%)	140 (63.6%)	220
Total	100 (21.7%)	360 (78.3%)	460

• Absolute Risk Reduction (ARR): $8.3\% - 36.4\% = -28.1\%$

• Number Needed to Treat (NNT): $\frac{100}{28.1} = 3.55$

• Relative Risk Reduction (RRR): $\frac{8.3\%}{36.4\%} \times 100 = 22.8\%$

• Risk Ratio (RR): $\frac{20/240}{80/220} = 0.229$

• Odds Ratio (OR): $\frac{20/220}{80/140} = 0.159$

Diagnostic Test Performance: PSA Screening

PSA Test	Prostate Cancer Yes	Prostate Cancer No	Total
PSA +ve	21 (true positive)	6 (false positive)	27
PSA -ve	79 (false negative)	94 (true negative)	173
Total	100	100	200

• Sensitivity: $\frac{21}{100} = 0.21$ (21%)

• Specificity: $\frac{94}{100} = 0.94$ (94%)

• PPV: $\frac{21}{27} = 0.778$ (78%)

• NPV: $\frac{94}{173} = 0.543$ (54%)

Relative Risk: CHD and BMI

BMI	Death	Alive	Total
High	63	498	561
Low	21	558	579
Total	84	1056	1140

• Relative Risk (RR): $\frac{63/561}{21/579} = 3.09$

• Interpretation: High BMI increases risk of CHD death by 3 times compared to low BMI.

Clinical Trial Interpretation: Ranolazine vs Placebo

Primary and Secondary Endpoints

Clinical trials often report hazard ratios, confidence intervals, and p-values to assess treatment efficacy. The table below summarizes efficacy outcomes for Ranolazine vs Placebo:

Outcome	Ranolazine	Placebo	Hazard Ratio	95% CI	P Value
Primary end point	696 (21.8%)	735 (22.4%)	0.92	0.83-1.02	.11
Recurrent ischemia	217 (6.6%)	246 (7.5%)	0.87	0.72-1.04	.13
Cardiovascular death	107 (3.3%)	125 (3.8%)	0.89	0.68-1.16	.38
MI	236 (7.2%)	241 (7.3%)	0.98	0.81-1.18	.83
Failure of therapy	117 (3.6%)	135 (4.1%)	0.87	0.67-1.13	.29

Interpretation: The hazard ratio for the primary endpoint is 0.92 (95% CI: 0.83–1.02, p=0.11), indicating no statistically significant difference between Ranolazine and Placebo. For recurrent ischemia, HR is 0.87 (95% CI: 0.72–1.04, p=0.13), suggesting a trend toward benefit, but not statistically significant.

Additional info: A hazard ratio less than 1 favors the treatment, but statistical significance requires the confidence interval not to include 1 and a p-value less than 0.05.

Meta-Analysis and Clinical Decision-Making

Odds Ratio and Treatment Recommendations

Meta-analysis combines results from multiple studies to estimate effect size. In the SPAF II 75+ trial, the odds ratio for fatal outcomes was 1.1 (0.52–2.32), indicating no significant difference between warfarin and aspirin. Combined fatal and non-fatal events had an OR of 0.79 (0.61–1.02), suggesting a potential reduction in events with warfarin, but not statistically significant.

• Clinical Recommendation: Due to uncertainty and overlapping confidence intervals, more studies are needed before recommending long-term anticoagulation over antiplatelet therapy.

Summary Table: Key Biostatistical Concepts

Concept	Definition	Formula
Mean	Average value	$\frac{\sum x_i}{n}$
Standard Deviation	Spread of values	$\sqrt{\frac{\sum (x_i - \bar{x})^2}{n-1}}$
Risk Ratio	Risk comparison	$\frac{\text{Risk in treatment}}{\text{Risk in control}}$
Odds Ratio	Odds comparison	$\frac{\text{Odds in treatment}}{\text{Odds in control}}$
Sensitivity	True positive rate	$\frac{\text{True positive}}{\text{Total with disease}}$
Specificity	True negative rate	$\frac{\text{True negative}}{\text{Total without disease}}$
PPV	Positive predictive value	$\frac{\text{True positive}}{\text{Total test positive}}$
NPV	Negative predictive value	$\frac{\text{True negative}}{\text{Total test negative}}$
Hazard Ratio	Event rate comparison	Calculated from survival analysis